Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements examine located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By infl... https://roberth753hjk3.azuria-wiki.com/user